Results 121 to 130 of about 6,412,465 (299)

Renal‐vascular axis: unmasking its role in vascular endothelial growth factor‐inhibitor vascular toxicity in cancer patients

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Vascular toxicity is a growing concern in cancer patients receiving vascular endothelial growth factor inhibitor (VEGFi) therapy, posing a significant threat to patient prognosis. While the primary mechanism of VEGFi‐induced vascular toxicity is linked to redox‐sensitive reactions that disrupt vascular tone, leading to hypertension and ...
Grace Whelan, Karla B. Neves
wiley   +1 more source

Notoginsenoside‐Fa mitigates vascular endothelial permeability via targeting SUGT1 to stabilize NLRP3 in a resting state

open access: yesBritish Journal of Pharmacology, EarlyView.
Background and Purpose Notoginsenoside‐Fa (Noto‐Fa) is an emerging active compound derived from notoginseng with promise in treating cardiovascular diseases. The development of cardiovascular diseases is intricately linked to the damage of vascular endothelium and it is widely acknowledged that numerous chronic inflammation pathways, especially the ...
Xiao‐Ying Yu   +9 more
wiley   +1 more source

Primary postpartum hemorrhage in women with von Willebrand disease and carriers of hemophilia: a retrospective analysis

open access: yesResearch and Practice in Thrombosis and Haemostasis
Background: Between 2002 and 2011, the incidence of severe primary postpartum hemorrhage (PPH) in Dutch women with von Willebrand disease (VWD) and hemophilia carriers (HCs) was 8% vs 4.5% in the general population.
Marieke Punt   +16 more
doaj   +1 more source

The burden of COVID‐19 in hospitalized people with diabetes mellitus in Brazil: Insights from four years of the pandemic

open access: yesDiabetic Medicine, EarlyView.
Abstract Aims Coronavirus disease 2019 (COVID‐19), caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), is more severe in people with diabetes mellitus due to immune dysfunction, exacerbated inflammation and increased risk of co‐morbidities and mortality.
Taís Mendes Camargo   +4 more
wiley   +1 more source

Acquired von Willebrand syndrome: An update

open access: yes, 2007
Acquired von Willebrand syndrome (aVWS) is a rare bleeding disorder with laboratory findings similar to those for congenital von Willebrand disease (VWD).
LIPPI, Giuseppe, Franchini M
core   +1 more source

Dual Mechanism of Severe Bleeding Diathesis in a Patient with CLL: Acquired Von Willebrand Syndrome and Ibrutinib - Mediated Platelets Dysfunction [PDF]

open access: yes, 2020
We here report an informative case of severe bleeding diathesis in a patient with Chronic Lymphocytic Leukaemia (CLL), due to Acquired Von Willebrand Syndrome (AVWS) and impaired platelets aggregation under the treatment with Ibrutinib. Keywords:
Novak, U, Bürki, S
core   +1 more source

The Effect of Polycythemia Vera on Pregnancy Complications. The Analysis of an American Population Database With Over 9 Million Deliveries

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Objectives Polycythemia Vera (PV) is characterized by overproduction of erythrocytes, leading to a hypercoagulable state. Evidence regarding associations between PV and pregnancy outcomes is limited. The aim of our study was to provide robust evidence regarding the prevalence of pregnancy complications in women with PV.
Noah Margolese   +5 more
wiley   +1 more source

Retrospective study of multimers in von Willebrand disease

open access: yes
reservedIl fattore von Willebrand (VWF) è una glicoproteina multimerica essenziale per l’emostasi primaria, con i multimeri ad alto peso molecolare (HMWM) particolarmente cruciali per la corretta funzione emostatica.
SIMONI, ELENA
core  

Determinación del factor von Willebrand para la confirmación de la enfermedad de von Willebrand en Nicaragua

open access: yes, 2020
Von Willebrand's disease is the most frequent hemorrhagic diathesis worldwide affecting men and women. Currently, there are 3 types of von Willebrand ´s disease: type 1, 2A, 2B, 2M, 2N, and 3, with type 1 being the most frequent.
Bonilla, Orlando   +4 more
core  

Management of von Willebrand disease with factor VIII/von Willebrand factor concentrates: results from current studies and surveys

open access: yes, 2005
Until the mid 1980s, cryoprecipitate had been the mainstay of treatment of patients with von Willebrand disease (VWD) who were unresponsive to desmopressin.
A.B. Federici
core   +1 more source

Home - About - Disclaimer - Privacy